Full history for every metric is available with a Kvantra account
Galapagos N.V. (GLPG)
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 478 | 485 | 241 | 240 | 276 | 1,112 | 991 |
| Operating profit | €m | 501 | 403 | |||||
| Net profit | €m | -305 | -125 | -218 | 212 | 74 | 321 | 597 |
| EPS reported | € | 4.85 | 9.03 | |||||
| Operating cashflow per share | € | -2.87 | -4.22 | |||||
| Capex per share | € | 0.20 | 0.12 | |||||
| FCF per share | € | -3.07 | -4.35 | |||||
| Free cash flow | €m | -202 | -305 | |||||
| Net debt | €m | -2,997 | -2,982 | |||||
| Book value equity | €m | 3,234 | 3,253 | |||||
| Book value per share | € | 49.09 | 46.46 | |||||
| Number of shares | m | 65.89 | 70.03 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 5.74 | 2.63 | |||||
| P/B LTM | x | 0.57 | 0.50 | |||||
| P/S LTM | x | 1.65 | 1.65 | |||||
| P/FCF LTM | x | -9.06 | -5.38 | |||||
| EV/EBITDA LTM | x | 4.88 | -5.14 | |||||
| EV/Sales LTM | x | 1.58 | -1.36 | |||||
| Earnings Yield LTM | % | 17.42% | 38.02% | |||||
| FCF Yield | % | -11.04% | -18.59% | |||||
| Quality | ||||||||
| ROE | % | 9.92% | 19.88% | |||||
| ROIC | % | 15.41% | 12.31% | |||||
| Operating margin | % | 45.08% | 40.67% | |||||
| Gross margin | % | 97.33% | 97.44% | |||||
| FCF/Sales | % | -18.20% | -30.74% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +333.04% | - | |||||
| Sales Growth YoY | % | +303.50% | +259.49% | |||||
| Net Income Growth YoY | % | +333.15% | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -29.27 | -47.33 | |||||
| Net Debt/EBITDA | x | -0.23 | -0.23 | |||||
| EBIT/Net interest | x | 226.16 | 16.36 | |||||
| Net debt/market cap | % | -163.41% | -182.08% | |||||
| Net debt/Equity | x | -0.93 | -0.92 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Galapagos N.V. (GLPG)
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free